IN

Inhibitor Therapeutics IncOOTC INTI Stock Report

Last reporting period 30 Sep, 2023

Updated 11 Nov, 2024

Last price

Market cap $B

0.014

Micro

Exchange

OOTC - OTC

INTI Stock Analysis

IN

Uncovered

Inhibitor Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.014

Dividend yield

Shares outstanding

376.86 B

Inhibitor Therapeutics, Inc. engages in the discovery, development, and commercialization of therapeutics for patients with cancer. The company is headquartered in Tampa, Florida and currently employs 1 full-time employees. The firm is focused on developing and commercializing therapeutics for patients with certain cancers and certain non-cancerous proliferation disorders. The firm is focused on development of its lead product, SUBA-Itraconazole, an oral formulation of anti-fungal drug, Itraconazole, for any prostate cancer, prostatic intraepithelial neoplasia and benign prostatic hyperplasia; lung cancer and atypical adenomatous hyperplasia. SUBA-Itraconazole is designed to enable absorption and reduced variability compared to generic itraconazole. The company is developing SUBA-Itraconazole prostate to address the unmet need for men with late-stage, metastatic castrate-resistant prostate cancer (mCRPC). The company is also developing SUBA-Itraconazole for lung cancer and locally advanced and metastatic basal cell carcinoma (BCC). SUBA-Itraconazole has completed Phase II b clinical trials.

View Section: Eyestock Rating